Slave, your post notes that "DCVax is not being held up because of volume. It is being evaluated based on how its therapy is made, because in autologous immunotherapy, the preparation is the product. That evaluation takes time, and it takes precision." While true, I thought how the therapy is made was known and detailed in the MAA, resulting in the formulation of the recent SI which would seem confirm that.
Market Data 
Markets 
AI
